CN1250253C - Chinese medicine capsule for treating ischemic cerebral apoplexy - Google Patents
Chinese medicine capsule for treating ischemic cerebral apoplexy Download PDFInfo
- Publication number
- CN1250253C CN1250253C CNB021551308A CN02155130A CN1250253C CN 1250253 C CN1250253 C CN 1250253C CN B021551308 A CNB021551308 A CN B021551308A CN 02155130 A CN02155130 A CN 02155130A CN 1250253 C CN1250253 C CN 1250253C
- Authority
- CN
- China
- Prior art keywords
- treatment
- preparation
- pharmaceutic adjuvant
- adds
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicine capsule for treating ischemic cerebral apoplexy and a preparation method thereof. The existing medicine for treating ischemic cerebral apoplexy is prepared from crude drugs and has the disadvantages of bad therapeutic effect and low effective rate. The present invention is characterized in that the Chinese medicine capsule for treating ischemic cerebral apoplexy is prepared from 10 to 25% of leeches, 5 to 10% of gadfly, 20 to 30% of rhubarb, 20 to 30% of peach kernels and 10 to 25% of pharmaceutic adjuvant. The present invention has the preparation method that the leeches and the gadfly are immersed by alcohol, percolated, concentrated, added with the pharmaceutic adjuvant, uniformly mixed and dried to obtain first dry ointment; the rhubarb and the peach kernels are decocted in water, added with ethanol, stirred, laid asides, filtered, concentrated, added with the pharmaceutic adjuvant, uniformly mixed and dried to obtain second dry ointment; the first dry ointment and the second dry ointment are mixed, pulverized and filled into capsules. According to the characteristics of animal medicines and plant medicines, the present invention respectively adopts different methods to extract effective ingredients, so the therapeutic effect of the medicines is improved. The total effective rate of the Chinese medicine capsule for treating apoplexy, apoplexy involving collateral and meridian, recovery stages and blood stasis syndromes can reach to 86.7%.
Description
Technical field
The present invention relates to Chinese patent medicine, specifically a kind of preparation method for the treatment of the Chinese medicinal capsule of ischemia apoplexy.
Background technology
Ischemia apoplexy is a cerebral infarction, and it comprises cerebral thrombosis, cerebral embolism etc., and cerebral infarction accounts for 70%～80% in all apoplexy, showed increased in recent years, and develop to rejuvenation.The main pathological change of cerebral infarction is on the basis of cerebral arteriosclerosis, form thrombosis in the blood vessel, blocked blood flow, cause ischemia, anoxia and the necrosis of cerebral tissue, make the people hemiplegia, aphasia, side numb limbs and tense tendons, shakiness, gatism, mental disorder, the dementia of walking even become the plant man partially occur, part brain stem infarct and Big Area Cerebral Infarction can be fatal.In case suffer from cerebral infarction, illustrate that body has possessed thrombosed three classes basis factor, factors such as the damage of blood vessel endothelium, the change of blood matter, hemodynamic change, these factors will be sent out repeatedly as can not get effective control again.The apoplexy Therapeutic Method of the traditional Chinese medical science is multifarious, have their own characteristics each, wherein activating blood and removing stasis Method and eliminating heat pathogen by purging the bowels method are present clinical experiment and the most normal method that is used of scientific research, also are present effect two methods preferably, wherein again with the tool modernization of activating blood and removing stasis Method pharmacology basis.In the existing medicine according to " activating blood and removing stasis Method " theoretical preparation, Hirudo, Tabanus etc. are many in patent medicine is used as medicine with crude drug, and human body is low to the absorbance of its active component, thereby therapeutic effect is not fine, effective percentage is lower, and simultaneously required medical material amount is big, causes the waste of Chinese material medicine resource.
Summary of the invention
Technical problem to be solved by this invention provides a kind of removing blood stasis, the network that stimulates the menstrual flow, active component content height, good effect, be used for the treatment of new Chinese medicinal capsule of ischemia apoplexy and preparation method thereof.
Technical scheme of the present invention is such: the Chinese medicinal capsule of treatment ischemia apoplexy, it is characterized in that it is to be made by following weight percentages: Hirudo 10-25%, Tabanus 5-10%, Radix Et Rhizoma Rhei 20-30%, Semen Persicae 20-30% and pharmaceutic adjuvant 10-25%.Hirudo, Tabanus are the specification of stipulating on the Chinese Pharmacopoeia (coarse powder), the present invention is based on " activating blood and removing stasis Method " of theory of Chinese medical science, Hirudo, Tabanus, Radix Et Rhizoma Rhei and Semen Persicae are combined by certain weight ratio, and the alcohol extract anticoagulation of Hirudo, anti thrombotic action are stronger; The Tabanus blood circulation promoting and blood stasis dispelling, network stimulates the menstrual flow, blood viscosity, thrombolytic effect change, the extracting solution of Semen Persicae has the effect of anticoagulant and more weak haemolysis, and the decoction alcohol precipitation method extract of Radix Et Rhizoma Rhei has the effect of dissolution and eliminating blood stasis and inducing menstruation to rabbit ear edge phlebothrombosis.The present invention creatively is used for the treatment of ischemia apoplexy with the blood circulation invigorating efficacies of said components, has obtained significant curative effect.Show through a large amount of clinical trials, the present invention to apoplexy hemiplegia, crooked mouth and tongue, the stiff tongue speech is not smoothgoing or in silence, syndrome such as hemianesthesia improves significantly; Can reduce whole blood and plasma viscosity, thereby reduce the chance of sending out infraction again, effectively the development of disease controlling helps the recovery of the state of an illness; The total effective rate of treatment apoplexy, apoplex involving the channels and collaterals, convalescent period and Blood stasis reaches 86.7%, finds no any toxic and side effects.
The Chinese medicinal capsule of described treatment ischemia apoplexy, pharmaceutic adjuvant are a kind of or both combinations in starch, the silicon dioxide, and in addition, pharmaceutic adjuvant can also be selected dextrin, microcrystalline Cellulose, carboxymethyl starch sodium etc. for use.Silicon dioxide reduces the viscosity of extractum, makes it easy drying, plays dampproof effect, accelerates the speed when vacuum drying.
Another technical scheme of the present invention is: the preparation method of the Chinese medicinal capsule of treatment ischemia apoplexy, and it may further comprise the steps:
A, with concentration be the methanol of 45-80% or ethanol to the dry product (coarse powder) of Hirudo and Tabanus soak into, percolation 24-50 hour, percolation speed is the 1.5-3.0 ml/min, the percolate of gained is evaporated to concentrated solution under 40-90 ℃ relative density is 1.24-1.38 (40 ℃), the pharmaceutic adjuvant that adds the 2-8% of drug weight then, at 20-65 ℃ of following vacuum drying, get dry extract behind the mixing;
B, in Radix Et Rhizoma Rhei and Semen Persicae, decoct with water, the decoction liquor of gained is filtered, the relative density that filtrate decompression is concentrated into concentrated solution is 1.01-1.05 (60 ℃), add ethanol and stir, left standstill 8-12 hour, filter, the relative density that filtrate decompression is concentrated into concentrated solution is 1.24-1.28 (60 ℃), the pharmaceutic adjuvant that adds the 6-13% of drug weight then at 50-90 ℃ of following vacuum drying, gets dry extract behind the mixing;
C, the dried cream that will be made by a step and merged by the dried cream that the b step makes pulverizes, and adds the pharmaceutic adjuvant of the 2-4% of medicine weight, crosses 30-120 purpose sieve, and mixing is in incapsulating.
The preparation method of the Chinese medicinal capsule of described treatment ischemia apoplexy, be secondary decocting with water of b step, the weight that adds for the first time entry is Radix Et Rhizoma Rhei and Semen Persicae gross weight 5-10 times, decocting time is 1-3 hour, the weight that adds for the second time entry is Radix Et Rhizoma Rhei and Semen Persicae gross weight 3-8 times, decocting time is 1-3 hour, and collecting decoction decocts secondary and can improve paste volume and save cost.
The preparation method of the Chinese medicinal capsule of described treatment ischemia apoplexy, used concentration of ethanol is 60% in a step, its consumption is Hirudo and Tabanus gross weight 6-15 a times; The ethanol that adds in the b step is measured at 60-80% the alcohol that contains in molten night.
The preparation method of the Chinese medicinal capsule of described treatment ischemia apoplexy, the moisture content of the dried cream that is made by a, b two steps is 2-7%, used vacuum is 0.07-0.09Mpa.
The extraction that Chinese crude drug is carried out active component (effective ingredient) at present mainly adopts ethanol percolate extraction and low temperature to reclaim solvent and decoction alcohol precipitation method extracts two kinds of methods, because of animal drugs decoction meeting in water causes a large amount of active component to extract because of proteinic solidifying, thereby influenced the curative effect of medicine, innovation part of the present invention is at a, in the b step animal drugs and plant amedica are adopted the ethanol percolation extract at low temperature respectively, decoction alcohol precipitation method extracts active component separately, active component in the animal drugs is extracted more completely, both reduce cost, improved the therapeutic effect of medicine again.Through experimental results demonstrate, the animal drugs among the present invention is more much better than than the anticoagulant effect that decoction alcohol precipitation method extracts the extracting solution that obtains with ethanol percolate extraction.
The present invention is theoretical based on " activating blood and removing stasis Method " of the traditional Chinese medical science, Hirudo, Tabanus, Radix Et Rhizoma Rhei and Semen Persicae are combined by certain weight ratio, characteristic according to animal drugs and plant amedica, adopt diverse ways to carry out the extraction of effective ingredient respectively to them, effective ingredient in the medicine is extracted more completely, improved the therapeutic effect of medicine; The capsule that the present invention makes has tangible thrombolytic effect, and cerebral blood flow increasing amount and reduction cerebral vascular resistance have obviously suppressed platelet aggregation, suppress the formation of thrombosis, have reduced paralytic's disability rate, reduce the recurrence of cerebral infarction.Through acute toxicology and long term toxicity test, do not find toxic and side effects and untoward reaction.
Utilize the case of the Chinese medicinal capsule treatment ischemia apoplexy that the present invention makes the present invention is further illustrated below by embodiment with in clinical.
The specific embodiment
Embodiment 1 takes by weighing Chinese medicine: Hirudo 386.3g, Tabanus 193.2g, Radix Et Rhizoma Rhei 579.5g, Semen Persicae 579.2g and pharmaceutic adjuvant 205.0g.
With the concentration of 2 times of doses 60% ethanol to the coarse powder dipping of Hirudo and Tabanus after 12 hours, the ethanol that adds 10 times of doses carried out percolation 48 hours, percolation speed is 2.0 ml/min, the percolate of gained is 1.25 (40 ℃) in the relative density that is evaporated to concentrated solution below 50 ℃, the silicon dioxide that adds 78.2g then, at vacuum drying below 50 ℃, get dry extract behind the mixing; Decoct with water secondary in Radix Et Rhizoma Rhei and Semen Persicae, the weight that adds entry for the first time is Radix Et Rhizoma Rhei and Semen Persicae gross weight 8 times, and decocting time is 1.5 hours, and the weight that adds entry for the second time is Radix Et Rhizoma Rhei and Semen Persicae gross weight 5 times, and decocting time is 1.5 hours.The decoction liquor of gained is filtered, the relative density that filtrate decompression is concentrated into concentrated solution is 1.03 (60 ℃), adding ethanol is 70% to containing the alcohol amount, stir, left standstill 10 hours, filter, the relative density that filtrate decompression is concentrated into concentrated solution is 1.27 (60 ℃), add 104.3g starch then, vacuum drying below 70 ℃ (vacuum is 0.08 Mpa), get dry extract behind the mixing; To be merged by the dried cream (moisture content is 3%) that above-mentioned steps makes and pulverize, and add 22.5g starch, and cross 60 purpose sieves, mixing gets 685g, in incapsulating.
Embodiment 2
Take by weighing Chinese medicine: Hirudo 420g, Tabanus 160g, Radix Et Rhizoma Rhei 600g, Semen Persicae 560g and pharmaceutic adjuvant 265g.
With the concentration of 2 times of doses 50% ethanol to the coarse powder dipping of Hirudo and Tabanus after 12 hours, the ethanol that adds 10 times of doses carried out percolation 38 hours, percolation speed is 2.5 ml/min, the percolate of gained is 1.27 (40 ℃) in the relative density that is evaporated to concentrated solution below 60 ℃, the silicon dioxide that adds 78g then, at vacuum drying below 60 ℃, get dry extract behind the mixing; Decoct with water secondary in Radix Et Rhizoma Rhei and Semen Persicae, the weight that adds entry for the first time is Radix Et Rhizoma Rhei and Semen Persicae gross weight 6 times, and decocting time is 2 hours, and the weight that adds entry for the second time is Radix Et Rhizoma Rhei and Semen Persicae gross weight 5 times, and decocting time is 1.5 hours.The decoction liquor of gained is filtered, the relative density that filtrate decompression is concentrated into concentrated solution is 1.04 (60 ℃), adding ethanol is 70% to containing the alcohol amount, stir, left standstill 10 hours, filter, the relative density that filtrate decompression is concentrated into concentrated solution is 1.26 (60 ℃), the starch that adds 104g then in 70 ℃ of following vacuum (vacuum is 0.09Mpa) drying, gets dry extract behind the mixing; To be merged by the dried cream (moisture content is 4%) that above-mentioned steps makes and pulverize, and add the starch of 83g, and cross 60 purpose sieves, mixing gets 705g, in incapsulating.
Further specify the present invention below by the clinical trial case.
Test case 450 examples are divided into two groups, and 300 examples are organized in matched group 150 examples and treatment, and group is taken the commodity Naoxuekang capsule for curing cerebrovascular disease (Shandong Province's Weishan Lake pharmaceutical factory) by name of medicine in contrast.Observe by clinical trial, according to the symptom evaluation criteria of keeping the score, record is taken the mark of back doing well,improving and is made statistics, the curative effect of its treatment group and matched group relatively and efficacy analysis as follows:
Curative effect compares:
1, treatment group and matched group curative effect compare: see Table 1
Table 1 liang group curative effect is (example) (ratio) relatively
| Be almost recovered | Produce effects | Effectively | Invalid | Total effective rate | u | P |
| Matched group | 5(3.3％) | 23(15.4％) | 75(50％) | 47(31.3％) | 68.7 | ||
| The treatment group | 21(7％) | 74(24.7％) | 165(55％) | 40(13.3％) | 86.7 | 4.13 | ＜0.01 |
Analyze through Ridit, two groups of curative effects have utmost point significant difference, P＜0.01, and the treatment group is better than matched group.
1, two groups to the aphasis curative effect relatively: see Table 2
Table 2 (example)
| Group | u | P | ||||||
| 0 | 1 | 2 | 3 | 4 | ||||
| The treatment group | Before the treatment | 77 | 16 | 78 | 90 | 39 | ||
| After the treatment | 114 | 90 | 63 | 20 | 13 | 7.86 | ＜0.01 | |
| Matched group | Before the treatment | 26 | 13 | 36 | 59 | 16 | ||
| After the treatment | 45 | 37 | 46 | 19 | 3 | 5.91 | ＜0.01 | |
Self compares before and after the treatment, and treatment group, matched group are analyzed through Ridit, all show significant difference (P＜0.01).Treat the back between group relatively, analyze through Ridit, u=2.25, there is significant difference P＜0.05, and the treatment group is better than matched group.
2, two groups to upper limb shoulder joint function obstacle curative effect relatively: see Table 3
Table 3 (example)
| Group | u | P | ||||||
| 0 | 1 | 2 | 3 | 4 | ||||
| The treatment group | Before the treatment | 1 | 2 | 77 | 164 | 56 | ||
| After the treatment | 36 | 97 | 121 | 30 | 16 | 14.4 | ＜0.01 | |
| Matched group | Before the treatment | 1 | 1 | 38 | 66 | 44 | ||
| After the treatment | 16 | 31 | 53 | 37 | 13 | 7.62 | ＜0.01 | |
Self compares before and after the treatment, and treatment group, matched group are analyzed through Ridit, all show significant difference (P＜0.01).Treat the back between group relatively, analyze through Ridit, u=3.39, there is significant difference P＜0.01, and the treatment group is better than matched group.
3, two groups to upper limb articulations digitorum manus dysfunction curative effect relatively: see Table 4
Table 4 (example)
| Group |
| 0 | 1 | 2 | 3 | 4 | u | P | ||
| The treatment group | Before the treatment | 1 | 1 | 50 | 171 | 77 | ||
| After the treatment | 24 | 68 | 148 | 34 | 26 | 13.81 | ＜0.01 | |
| Matched group | Before the treatment | 0 | 0 | 25 | 72 | 53 | ||
| After the treatment | 4 | 34 | 41 | 43 | 28 | 6.21 | ＜0.01 |
Self compares before and after the treatment, and treatment group, matched group are analyzed through Ridit, all show significant difference (P＜0.01).Treat the back between group relatively, analyze through Ridit, u=4.16, there is significant difference P＜0.01, and the treatment group is better than matched group.
5, two groups to lower limb hip joint function obstacle curative effect relatively: see Table 5
Table 5 (example)
| Group | u | P | ||||||
| 0 | 1 | 2 | 3 | 4 | ||||
| The treatment group | Before the treatment | 2 | 2 | 115 | 149 | 32 | ||
| After the treatment | 42 | 139 | 89 | 25 | 5 | 15.47 | ＜0.01 | |
| Matched group | Before the treatment | 2 | 5 | 57 | 57 | 29 | ||
| After the treatment | 19 | 53 | 45 | 26 | 7 | 8.01 | ＜0.01 | |
Self compares before and after the treatment, and treatment group, matched group are analyzed through Ridit, all show significant difference (P＜0.01).Treat the back between group relatively, analyze through Ridit, u=2.61, there is significant difference P＜0.01, and the treatment group is better than matched group.
6, two groups to lower limb toe joint dysfunction curative effect relatively: see Table 6
Table 6 (example)
| Group | u | P | ||||||
| 0 | 1 | 2 | 3 | 4 | ||||
| The treatment group | Before the treatment | 0 | 1 | 64 | 174 | 61 | ||
| After the treatment | 19 | 110 | 119 | 38 | 14 | 14.83 | ＜0.01 | |
| Matched group | Before the treatment | 0 | 0 | 26 | 79 | 45 | ||
| After the treatment | 8 | 42 | 49 | 24 | 27 | 7.46 | ＜0.01 | |
Self compares before and after the treatment, and treatment group, matched group are analyzed through Ridit, all show significant difference (P＜0.01).Treat the back between group relatively, analyze through Ridit, u=3.26, there is significant difference P＜0.01, and the treatment group is better than matched group.
7, two groups to patient's comprehensive function curative effect relatively: see Table 7
| Group | u | P | ||||||
| 0 | 1 | 2 | 3 | 4 | ||||
| The treatment group | Before the treatment | 0 | 1 | 51 | 165 | 83 | ||
| After the treatment | 21 | 92 | 124 | 44 | 19 | 14.51 | ＜0.01 | |
| Matched group | Before the treatment | 0 | 0 | 12 | 84 | 54 | ||
| After the treatment | 7 | 25 | 62 | 30 | 26 | 8.08 | ＜0.01 | |
Self compares before and after the treatment, and treatment group, matched group are analyzed through Ridit, all show significant difference (P＜0.01).Treat the back between group relatively, analyze through Ridit, u=4.17, there is significant difference P＜0.01, and the treatment group is better than matched group.
8, two groups of treatment front and back tcm syndrome curative effects relatively: see Table 8
Table 8
| Before the treatment | After the treatment | |||||||||||
| + | ++ | +++ | - | + | ++ | +++ | - | u | P | |||
| The treatment group | Hemiplegia | 2 | 118 | 180 | 0 | 149 | 62 | 27 | 62 | 16.69 | ＜0.01 | |
| Crooked mouth and tongue | 58 | 117 | 73 | 52 | 124 | 38 | 13 | 125 | 10.31 | ＜0.01 | ||
| Stiff tongue speech is not smoothgoing or in silence | 35 | 103 | 93 | 69 | 93 | 54 | 18 | 135 | 9.06 | ＜0.01 | ||
| Hemianesthesia | 60 | 124 | 45 | 7l | 122 | 33 | 10 | 135 | 8.83 | ＜0.01 | ||
| Matched group | Hemiplegia | 2 | 65 | 83 | 0 | 55 | 59 | 19 | 17 | 9.46 | ＜0.01 | |
| Crooked mouth and tongue | 24 | 68 | 35 | 23 | 44 | 48 | 5 | 53 | 6.07 | ＜0.01 | ||
| Stiff tongue speech is not smoothgoing or in silence | 14 | 67 | 46 | 23 | 51 | 45 | 4 | 50 | 7.29 | ＜0.01 | ||
| Hemianesthesia | 26 | 73 | 15 | 36 | 61 | 28 | 4 | 57 | 5.21 | ＜0.01 | ||
Annotate :+expression is slight, ++ the expression moderate, +++expression severe ,-expression is normal.
Self compares before and after the treatment, and treatment group, matched group are analyzed through Ridit, all show significant difference (P＜0.01).Treat the back between group relatively, analyze hemiplegia u=4.04, P＜0.01 through Ridit; Crooked mouth and tongue u=2.59, P＜0.01; Not smoothgoing or the u=2.13 in silence of stiff tongue speech, P＜0.05; Hemianesthesia u=1.65, P＞0.05.The there was no significant difference, all the other proof treatment groups all are better than matched group except that between the hemianesthesia group.
9, hemorheology compares (n=120) before and after the treatment group treatment: see Table 9
Table 9
| Before the treatment | After the treatment | t | p | |
| Whole blood viscosity | Height is cut 4.57 ± 0.63 and low is cut 8.11 ± 2.83 | 4.37±0.39 7.47±2.15 | 2.96 1.97 | ＜0.01 ＜0.05 |
| Plasma viscosity | 1.83±0.21 | 1.77±0.13 | 2.66 | ＜0.01 |
| Fibrin | 3.03±0.65 | 3.17±0.54 | 1.81 | ＞0.05 |
As shown in Table 9, treatment group all has significant difference before and after hemorheology is treated except that fibrin.
10, blood pressure compares (n=300) before and after the treatment group treatment: see Table 10
Table 10
| Project | Before the treatment (X ± SD) | The treatment back (X ± SD) | t | p |
| Systolic pressure (kpa) | 19.6±3.06 | 18.7±2.16 | 4.162 | ＜0.01 |
| Diastolic pressure (kpa) | 12.3±1.71 | 11.2±1.32 | 8.819 | ＜0.01 |
By last table, through check, systolic pressure, diastolic pressure all have significant difference before and after the treatment, illustrate that the Chinese medicinal capsule that the present invention makes has the effect that brings high blood pressure down.
The safety observation of 11, treatment group
300 examples are organized in treatment, measure liver, renal function before and after the treatment respectively, blood, urine, just conventional, and Electrocardioscopy, the safety observed data sees Table 11
| Project | Before the treatment | After the treatment | ||
| Normally | Unusually | Normally | Unusually | |
| Routine blood test | 300 | 0 | 300 | 0 |
| Routine urinalysis | 300 | 0 | 300 | 0 |
| Just conventional | 300 | 0 | 300 | 0 |
| Liver function | 300 | 0 | 300 | 0 |
| Renal function | 300 | 0 | 300 | 0 |
| Electrocardiogram | 300 | 0 | 300 | 0 |
As seen from the above table, routine blood test, routine urinalysis before and after the treatment, just routine, liver function, kidney merit are all normal, do not find the ECG change patient in the treatment front and back, show that Chinese medicinal capsule of the present invention has good safety.
Efficacy analysis:
1, Chinese medicinal capsule treatment apoplexy of the present invention, apoplex involving the channels and collaterals, convalescent period, Blood stasis 300 examples, 21 examples that are almost recovered (7%), produce effects 74 examples (24.7%), effective 165 examples (55%), invalid 40 examples (13.33%), total effective rate reaches 86.7%.Illustrate that this product truly has good effect to Blood stasis, compare that there is significant difference P＜0.01, illustrate that Chinese medicinal capsule of the present invention is better than the curative effect of Naoxuekang capsule for curing cerebrovascular disease with the matched group NIAOXUEKANG.
2, by to the observation of apoplexy Blood stasis syndrome, before and after the treatment of treatment group significant difference is arranged all, this capsule is described the apoplexy hemiplegia, crooked mouth and tongue, the stiff tongue speech is not smoothgoing or in silence, the syndrome effect of having clear improvement such as hemianesthesia.
3, treatment group language function, integration is learned by statistics to handle significant difference is arranged before and after limb function and the comprehensive function treatment, illustrates that this product has significantly restitution to language function, limb function and comprehensive function.
4, by to observation on Hemorheology, can find that this product can reduce whole blood and plasma viscosity, thereby reduce the chance of sending out infraction again that the effectively development of disease controlling helps the state of an illness and recovers.
Claims (5)
1, the preparation method of the Chinese medicinal capsule of treatment ischemia apoplexy, the percentage by weight of each raw material is in the Chinese medicinal capsule: Hirudo 10-25%, Tabanus 5-10%, Radix Et Rhizoma Rhei 20-30%, Semen Persicae 20-30% and pharmaceutic adjuvant 10-25%, this preparation method may further comprise the steps:
A, with concentration be the methanol of 45-80% or ethanol to the dry product of Hirudo and Tabanus soak into, percolation 24-50 hour, percolation speed is the 1.5-3.0 ml/min, the percolate of gained is 1.24-1.28 being evaporated to the relative density of concentrated solution under 40 ℃ under 40-90 ℃, the pharmaceutic adjuvant that adds the 2-8% of drug weight then, at 20-65 ℃ of following vacuum drying, get dry extract behind the mixing;
B, in Radix Et Rhizoma Rhei and Semen Persicae, decoct with water, the decoction liquor of gained is filtered, it is 1.01-1.05 that filtrate decompression is concentrated into the relative density of concentrated solution under 60 ℃, add ethanol and stir, left standstill 8-12 hour, filter, it is 1.24-1.28 that filtrate decompression is concentrated into the relative density of concentrated solution under 60 ℃, the pharmaceutic adjuvant that adds the 6-13% of drug weight then at 50-90 ℃ of following vacuum drying, gets dry extract behind the mixing;
C, the dried cream that will be made by a step and merged by the dried cream that the b step makes pulverizes, and adds the pharmaceutic adjuvant of the 2-4% of medicine weight, crosses 30-120 purpose sieve, and mixing is in incapsulating.
2, the preparation method of the Chinese medicinal capsule of treatment ischemia apoplexy according to claim 1, it is characterized in that being secondary decocting with water of b step, the weight that adds for the first time entry is Radix Et Rhizoma Rhei and Semen Persicae gross weight 5-10 times, decocting time is 1-3 hour, the weight that adds for the second time entry is Radix Et Rhizoma Rhei and Semen Persicae gross weight 3-8 times, and decocting time is 1-3 hour.
3, the preparation method of the Chinese medicinal capsule of treatment ischemia apoplexy according to claim 1 and 2 is characterized in that used concentration of ethanol is 60% in a step, and its consumption is Hirudo and Tabanus gross weight 6-15 a times; The ethanol that adds in the b step is measured at 60-80% the alcohol that contains in molten night.
4, the preparation method of the Chinese medicinal capsule of treatment ischemia apoplexy according to claim 3 is characterized in that the moisture content of the dried cream that made by a, b two steps is 2-7%, and used vacuum is 0.07-0.09Mpa.
5, the preparation method of the Chinese medicinal capsule of treatment ischemia apoplexy according to claim 1 is characterized in that described pharmaceutic adjuvant is a kind of or both combinations in starch, the silicon dioxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021551308A CN1250253C (en) | 2002-12-10 | 2002-12-10 | Chinese medicine capsule for treating ischemic cerebral apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021551308A CN1250253C (en) | 2002-12-10 | 2002-12-10 | Chinese medicine capsule for treating ischemic cerebral apoplexy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1506097A CN1506097A (en) | 2004-06-23 |
| CN1250253C true CN1250253C (en) | 2006-04-12 |
Family
ID=34235736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021551308A Expired - Lifetime CN1250253C (en) | 2002-12-10 | 2002-12-10 | Chinese medicine capsule for treating ischemic cerebral apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1250253C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100374130C (en) * | 2005-12-28 | 2008-03-12 | 哈药集团三精千鹤制药有限公司 | Stasis expelling vessel freeing drip pill |
| CN102225076B (en) * | 2011-06-14 | 2012-10-10 | 重庆时珍阁普生药业有限公司 | Modified Maixuekang preparation, modified Maixuekang enteric-coated preparation as well as preparation methods and applications thereof |
| CN102335370B (en) * | 2011-09-30 | 2013-04-03 | 哈药集团三精千鹤制药有限公司 | Flavored medicinal composition for removing stasis and dredging collaterals, and preparation method thereof |
| CN102362905A (en) * | 2011-11-09 | 2012-02-29 | 哈药集团三精千鹤制药有限公司 | Method for preparing capsules for removing stasis and unblocking channels |
| CN102688308B (en) * | 2012-05-30 | 2014-10-22 | 代龙 | Traditional Chinese medicine composition for ischemic stroke treatment as well as preparation method and application thereof |
| CN103505532B (en) * | 2013-10-10 | 2015-02-25 | 北京康远制药有限公司 | Traditional Chinese medicinal granules capable of removing blood stasis and preparation method thereof |
| CN115813985B (en) * | 2022-12-24 | 2024-03-12 | 浙江得恩德制药股份有限公司 | A Chinese medicinal capsule for treating cerebral apoplexy, and its preparation method |
-
2002
- 2002-12-10 CN CNB021551308A patent/CN1250253C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1506097A (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN1857664A (en) | Apoplexy treating preparation and its preparing process | |
| CN101214288B (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN1250253C (en) | Chinese medicine capsule for treating ischemic cerebral apoplexy | |
| CN100509009C (en) | A Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and ischemic apoplexy, and its preparation method | |
| CN1927279A (en) | Chinese medicine composition for treating skin disease | |
| CN100509010C (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1679698A (en) | Medicinal preparation containing notoginseng and lovge rhizome for treating cardio-cerebral blood vessel diseases and its preparing method | |
| CN1771978A (en) | Notoginseng triol-saponin composition and its prepn and use | |
| CN1954872A (en) | Traditional Chinese medicine composite and its preparation method | |
| CN103751450A (en) | Composition for treating diabetic nephropathy | |
| CN103479711A (en) | Application of eucommia ulmoides lignans extracts in preparation of medicine treating renal interstitial fibrosis | |
| CN1319578C (en) | Prescription of Chinese medicine compound preparation, its preparation method and use | |
| CN1857683A (en) | Compound Chinese medicine preparation for eliminating heat, promoting urination and dispersing blood clots and its preparing process | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN1559523A (en) | Naodesheng soft capsule and its preparation method | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN1876128A (en) | A medicine for treating metrorrhagia and preparation process thereof | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN106177250A (en) | A kind of Chinese medicine composition treating chronic nephritis | |
| CN1927366A (en) | Traditional Chinese medicine composition for treating chronic enterogastritis | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN100515466C (en) | Chinese medicine preparation for treating stroke | |
| CN106511539A (en) | Application of Naoxintong traditional Chinese medicine composition in preparing blood sugar reducing drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 312560 No. 2 National Road East, Xinchang, Zhejiang Patentee after: ZHEJIANG DND PHARMACEUTICAL CO.,LTD. Address before: 312560 No. 2 National Road East, Xinchang, Zhejiang Patentee before: ZHEJIANG DND PHARMACEUTICAL CO.,LTD. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060412 |